Home
overview

Following our successful conferences on the drug delivery industry, SMi have produced an update on the crucial issues surrounding commercial opportunities within this field. Incorporating drug delivery technologies early in the development of new drugs greatly increases the prospect for the drug. In this environment it is essential that drug delivery and pharma companies form close links. An outstanding panel of speakers will address the requirements of both types of companies when evaluating potential partnerships. They will present strategies for commercial success for both big and small drug delivery companies

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Sharon Finch

Sharon Finch, Managing Director, Medius

9:10 SMITHKLINE BEECHAM: EFFICIENT PRODUCT DEVELOPMENT

Dr Susan Scott

Dr Susan Scott, Project Director, SmithKline Beecham

  • Using drug delivery systems to enhance the product potential
  • Choosing the optimum system
  • Sources of technology - strategic alliances
  • Benefits and disadvantages of alliances
  • Dealing with patent issues
  • 9:40 ZENECA: TEAMING UP WITH DRUG DELIVERY COMPANIES

    Paul Gellert

    Paul Gellert, Team Leader, Drug Delivery, Pharmaceutical Research Group, Zeneca

  • Profiling drug candidates
  • Identifying delivery systems
  • Establishing collaborations with external technology providers
  • Application of drug delivery systems
  • Incorporating drug delivery technologies into the research phase
  • Future considerations on promising drug delivery technologies
  • 10:20 EXPLOITING COMMERCIAL OPPORTUNITIES

    Lewis H Bender

    Lewis H Bender, Senior Vice President, Business Development, Emisphere Technologies

  • New delivery systems: how can a product’s value be increased?
  • Tailoring the delivery system to provide improved value for a drug product (case in point examples)
  • Developing valuation models: applying drug delivery systems to existing products to maximise benefit
  • Changing to new delivery systems: how can product value be increased?
  • Structuring a drug delivery deal to minimise risk for both partners
  • Creating a 'win-win' partnership
  • 11:00 Morning Coffee

    11:20 DURA PHARMACEUTICALS: COLLABORATION STRATEGIES

    Vincent Gotz

    Vincent Gotz, Senior Director, Business Development, Dura Pharmaceuticals

  • Strengthening their commercial position
  • Growth strategy: in-licensing, aquiring and developing late stage pharmaceuticals
  • Pulmonary delivery of small molecules and macromolecules
  • Formulation development and manufacturing the final product in Spiros
  • Development of new drugs through collaborations with corporate partners
  • Growth prospects
  • 12:00 ARADIGM: SUCCESSFUL COLLABORATIONS

    Jerry Beers

    Jerry Beers, Executive Vice President, Business Development and Marketing, Aradigm

  • Expanding their commercial opportunity
  • Adding value to insulin products with novel drug delivery systems
  • Designing an alternative to administering medication by injection
  • Benefits of collaborations
  • Establishing joint development programs
  • Securing their position within the marketplace
  • 14:00 SUCCESSFULLY GAINING MARKET SHARES

    Dr Stefan Arver

    Dr Stefan Arver, Vice President, European Business Development, TheraTech

  • The development of TheraTech
  • The future direction of the product base
  • The role of drug delivery systems
  • Planned merger with Watson Pharmaceuticals
  • International partnerships
  • Targeting and gaining market share through industry alliances
  • 14:40 LAPHAL LABORATORIES: INDUSTRIAL AND COMMERCIAL PARTNERSHIPS

    Jean-Yves Leroy

    Jean-Yves Leroy, Director, Business Development, Laphal Laboratories

  • Growing through partnerships
  • Strategies for establishing mutually beneficial projects
  • Guidelines for networking at a global level
  • Sharing costs of development programs
  • Designing effective responses to future challenges
  • 15:20 Afternoon Tea

    15:40 MAXIMISING THEIR PROFITABILITY

    Dr David Prior

    Dr David Prior, Vice President, Scientific Affairs, Fuisz Technologies

  • Competing in the oral drug delivery sector
  • Cost-effect production of microspheres offering unique properties
  • Application to controlled release delivery systems
  • Application to taste-masking and convenience dosage forms
  • Creation of multiple line extensions from a single microsphere component
  • 16:20 ANESTA: CREATING THEIR POSITION

    Thomas B King

    Thomas B King, President and Chief Executive Officer, Anesta

  • Increasing the commercial value of a product via drug delivery systems
  • Producing drug delivery system product portfolios
  • Developing and registering new products based on off-patent drugs
  • Joining into alliances and other global strategies
  • Assessing the future developing of drug delivery companies
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration and Coffee

    9:00 Chairman’s Opening Remarks

    Dr Ian Wilding

    Dr Ian Wilding, Chief Executive, Pharmaceutical Profiles

    9:10 SEEING THINGS DIFFERENTLY: TEAM PARTNERSHIPS

    Dr John Siebert

    Dr John Siebert, President and Chief Executive Officer, CIMA LABS

  • Drug delivery IS making a difference
  • Paradigm changes
  • How to take advantage of the changes
  • Can we gain by working together?
  • Let’s start a new paradigm
  • 9:40 PARTNERSHIP REQUIREMENTS

    Dr Trevor Jarman

    Dr Trevor Jarman, Director, Business Development, Alizyme

  • Bridging the gap between science and the marketplace
  • In-licensing/out-licensing strategies
  • Concentrating on colonic delivery
  • Focusing on attractive markets
  • Identifying appropriate partners
  • 10:20 ALZA: BUILDING A STRONG COMMERCIAL PRESENCE

    Suzanne C Martin

    Suzanne C Martin, Vice President, Development Programs, ALZA Corporation

  • Transforming the company into a fully fledged commercial pharmaceutical firm
  • Forming alliances with other drug makers
  • Boosting the product pipeline
  • Developing new delivery technologies
  • Targeting specialty market opportunities
  • Aligning the project management structure to enhance product development
  • 11:00 Morning Coffee

    11:20 ASSESSING THE BEST LICENSING OPPORTUNITIES TO ACHIEVE A COMPETITIVE ADVANTAGE

    Dr Chris Searcy

    Dr Chris Searcy, Vice President, New Business Opportunities, Inhale Therapeutics

  • Securing company wide involvement in the search for new opportunitie
  • Identifying the most productive source of licensing opportunities
  • Communication with RandD to identify the most promising projects
  • Early evaluating the product’s commercial potential
  • Establishing world-wide patent status and ownership
  • Ensuring communication between RandD and licensing are effective to exploit the commercial opportunities
  • 12:00 KNOLL: STRATEGIES FOR LIFE CYCLE MANAGEMENT

    Dr Jörg Breitenbach

    Dr Jörg Breitenbach, Director, Product and Technological Development Extrusion, Knoll

  • Methods for extending product life cycles
  • Managing patent protection
  • Maximising pharmacoeconomic benefit
  • The use of enabling technologies
  • Selecting the right projects
  • Liaising with suitable partners
  • 12:40 Lunch

    13:40 SHIRE: CASE STUDY

    Dr Krystyna Belendiuk

    Dr Krystyna Belendiuk, Senior Vice President, Business Development, Shire Laboratories

  • Advantages of a broad portfolio of drug delivery techno
  • Managing operating and financial risk
  • Selectively involving multi-national partners
  • Developing their own product pipeline
  • Development of improved formulations on behalf of other pharmaceutical firms
  • Establishing a rapidly-growing market share
  • 14:20 MARKETING YOUR OWN PRODUCT

    Pauline Goldsmith

    Pauline Goldsmith, Senior Director, Business Development, Noven Pharmaceuticals

  • Prerequisites for marketing your own product
  • Identifying the costs and benefits of marketing your own product
  • Deciding what distribution channel is appropriate
  • Developing a marketing capability
  • Exploiting the commercial opportunities of going it alone
  • Managing the risks of going it alone
  • 15:00 EURAND: MAXIMISING THEIR POTENTIAL IN THE FUTURE

    Gearóid M Faherty

    Gearóid M Faherty, Managing Director, Eurand

  • Living for today but with a long term focus
  • Delivering on the promise
  • The danger of giving away the shop
  • Pharma company in training
  • 15:40 Afternoon Tea

    16:00 DELIVERING COST EFFECTIVE SOLUTIONS FOR THERAPEUTIC PROBLEMS

    Dr Paul Wotton

    Dr Paul Wotton, Vice President, Business Development, Penwest Pharmaceuticals

  • Delivering improved manufacturing efficiencies
  • Lowering the costs of production for pharmaceutical manufacturers
  • Important potential benefits for the patient
  • Which technologies come next?
  • Commercial impact of future technologies
  • Choosing the right partners
  • 16:30 WEST PHARMACEUTICAL SERVICES (DANBIOSYST): MAXIMISING THEIR POTENTIAL IN THE FUTURE

    Prof Stanley S Davis

    Prof Stanley S Davis, Chairman, t Pharmaceutical Services (DanBioSyst)

  • Finding delivery solutions for complex drug molecules
  • Building a portfolio of innovative drug delivery technologies
  • Successfully filing patent applications
  • Establishing development contracts with major pharmaceutical companies
  • Strategies for developing extensive contacts with the pharma industry as a whole
  • Changes in the pharmaceutical industry influencing the drug delivery industry
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    +

    Workshops

    Thistle Westminster

    Buckingham Palace Road
    London SW1W 0QT
    United Kingdom

    Thistle Westminster

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.